RVL Pharmaceuticals plc (RVLPQ)

Market Cap	111.00 -100.0%
Revenue (ttm)	36.92M +5.6%
Net Income	-68.27M
EPS	-0.70
Shares Out	111.41M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	600
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	n/a
Beta	40.53
Analysts	n/a
Price Target	1.60 (+15,999,900.0%)
Earnings Date	Aug 14, 2026

About RVL Pharmaceuticals

RVL Pharmaceuticals plc operates as a specialty pharmaceutical company in the United States, Argentina, and Hungary. It focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas. It is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and chan...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Brian Markison
• Employees: 125
• Stock Exchange: OTCMKTS
• Ticker Symbol: RVLPQ

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jun 19, 2026

Data Sources Report a data error